ELDN: Rega marang dodolan Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals is facing a cash shortage due to costly final-stage trials. Nevertheless, the medical community values the company for its breakthrough developments in transplantology. ESG principles and research ethics complement the development strategy. The revenue multiple reflects market expectations, with the indicator reaching , which helps assess the current business valuation.
Rincian analitis perusahaan Eledon (ELDN)
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- statistik kawajiban utang lan likuiditas:
Utang marang Modal Eledon Pharmaceuticals|ELDN - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang modal Eledon Pharmaceuticals, Inc|ELDN - Utang perusahaan|Utang-utang marang nilai buku Eledon|ELDN - Utang jangka dawa perusahaan|Tanggungan utang jangka cendhak perusahaan Eledon Pharmaceuticals|Rasio jangkoan perantara eledon.com
- data bathi lan kelipatan valuasi:
ELDN - Bathi resik perusahaan|Bathi forward Eledon Pharmaceuticals|ELDN - Pangali P/E|Pangali mangsa ngarep rega marang bathi Eledon Pharmaceuticals Inc.|ELDN - Pangali PEG|Pangali EV/EBITDA Eledon|ELDN - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajroning taun lumaku Eledon Pharmaceuticals|ELDN - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan eledon.com|ELDN - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Eledon Pharmaceuticals
- data total pendapatan lan volume dodolan:
Analisis fundamental perusahaan:ELDN - eledon.com
To protect capital amid volatility, the investor utilizes the market capitalization-to-annual revenue ratio, which allows for the identification of asset overvaluation relative to actual cash flow. Analyzing the price-to-sales ratio helps assess the business efficiency of Eledon Pharmaceuticals (ELDN), taking into account the costs of environmental laboratory modernization and the implementation of filtration systems within its immunological developments.
Pesaing Eledon Pharmaceuticals
argenx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S BNTX (BioNTech)|Abivax Pharma (ABVX) - Rega marang dodolan|ADMA Bio - Multiplikator P/S|Rega marang dodolan Protagonist Corp|Immunovant, Inc. (IMVT) - Rasio rega marang pendapatan|KNSA (kiniksa.com) - Rasio rega marang pendapatan|GRFS (Grifols) - Multiplikator P/S|Rega marang dodolan Adaptive Biotech ADPT|Multiplikator P/S CLDX|Aurinia Corp - Rasio kapitalisasi marang pendapatan|Rasio rega marang pendapatan BioCryst BCRX|veratx.com (VERA) - Rega marang dodolan|DNTH - Rasio rega marang pendapatan|PHVS (Pharvaris NV) - Rasio kapitalisasi marang pendapatan|ABCL (AbCellera Biologics Inc) - Kapitalisasi marang pendapatan|Tourmaline - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Precigen, Inc.|pharming.com - Rasio rega marang dodolan|Multiplikator P/S NKTR|UPB (Upstream Bio, Inc.) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ZBIO (Zenas Biopharma, Inc.)|Multiplikator P/S Immunome Bio IMNM|GOSS - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan KALV (kalvista.com)|Septerna (SEPN) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan Pieris Pharma|SVRA (Savara Corp) - Multiplikator P/S|Multiplikator P/S Rigel Corp|Multiplikator P/S ANAB|Kapitalisasi marang pendapatan astriatx.com ATXS|Multiplikator P/S ENGN (enGene)|RAPT Therapeutics Inc. (RAPT) - Rega marang dodolan|JBIO: Kapitalisasi marang pendapatan|ACRS - Multiplikator P/S|KYTX (Kyverna Therapeutics) - Kapitalisasi marang pendapatan|TLSA: Kapitalisasi marang volume dodolan|CABA (Cabaletta Bio) - Multiplikator P/S|Ventyx Biosciences Inc. (VTYX) - Koefisien rega marang pendapatan|Multiplikator P/S THTX|Kapitalisasi marang pendapatan Avalo Therapeutics Inc AVTX|Multiplikator P/S AGEN (Agenus)|Multiplikator P/S climbbio.com CLYM|ZURA - Rasio rega marang pendapatan|ATYR: Rasio rega marang pendapatan|adagene.com (ADAG) - Rasio rega marang pendapatan|IMA - Koefisien rega marang pendapatan|STTK (Shattuck Labs Inc) - Multiplikator P/S|Rega marang dodolan Equillium Bio EQ|Rasio rega marang pendapatan Connect Biopharma (CNTB)|Rasio rega marang pendapatan IMUX (immunic-therapeutics.com)|Multiplikator P/S ATRA (Atara Bio)|IFRX: Rasio kapitalisasi marang pendapatan|XFOR - Rasio rega marang pendapatan|ACET (Adicet Bio) - Rasio kapitalisasi marang pendapatan|celularity.com (CELU) - Rasio rega marang pendapatan|Rasio rega marang dodolan INMB (INmune Bio Inc)|BRNS (Barinthus Bio) - Multiplikator P/S|KZR: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S SABS|Multiplikator P/S akaritx.com (AKTX)|Rasio rega marang pendapatan Enlivex Therapeutics Ltd. ENLV|Rasio kapitalisasi pasar marang pendapatan QTTB|GOVX - Rasio rega marang pendapatan|Edesa Biotech Corp (EDSA) - Kapitalisasi marang pendapatan|IBIO: Multiplikator P/S|Carisma Therapeutics Inc. (CARM) - Multiplikator P/S|Kapitalisasi marang pendapatan XTLB|BOLT: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S HCWB|Koefisien rega marang pendapatan aptevotherapeutics.com|Rasio rega marang pendapatan AIM ImmunoTech Inc. AIM|ADTX - Kapitalisasi marang pendapatan|GRI - Rasio rega marang pendapatan|XORTX Therapeutics Inc (XRTX) - Kapitalisasi marang pendapatan|HIND (ReShape Lifesciences) - Kapitalisasi marang pendapatan|Revelation Biosciences Corp (REVB) - Multiplikator P/S|Rasio rega marang pendapatan Indaptus Therapeutics|Rasio kapitalisasi marang pendapatan SCNI (scinai.com)|Multiplikator P/S CALI|AFMD - Rega marang dodolan|Multiplikator P/S ALLK (Allakos)|HOOKIPA Pharma, Inc. (HOOK) - Rega marang dodolan|IGMS - Rasio rega marang pendapatan|ITOS: Rasio rega marang pendapatan|OCEA: Multiplikator P/S|Rega marang dodolan TC BioPharm (Holdings) Plc (TCBP)|THRD (Third Harmonic Bio, Inc) - Multiplikator P/S
